Journal article
High-Specific-Activity-I-131-MIBG versus Lu-177-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
Abhishek Jha, David Taieb, Jorge A Carrasquillo, Daniel A Pryma, Mayank Patel, Corina Millo, Wouter W de Herder, Jaydira Del Rivero, Joakim Crona, Barry L Shulkin, Irene Virgolini, Alice P Chen, Bhagwant R Mittal, Sandip Basu, Joseph S Dillon, Thomas A Hope, Carina Mari Aparici, Andrei H Iagaru, Rodney J Hicks, Anca M Avram Show all
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
Abstract
Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG) and peptide receptor radionuclide therapy (177Lu or 90Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-131I-MIBG therapy was approved by the FDA and both 177Lu-DOTATATE and 131I-MIBG therapy were recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. However, a clinical dilemma often arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin..
View full abstractGrants
Awarded by Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awarded by NIH, NCI Center Support grant
Funding Acknowledgements
This work was supported, in part, by the Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no., Z1AHD008735), and was supported, in part, by the NIH, NCI Center Support grant P30 CA008748.